The American Gastroenterology Association has published new expert recommendations in management of patients with COVID-19
The recommendations are published in Gastroenterology: AGA Institute Rapid Review of the GI and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19.
Key guidance
- GI symptoms are not as common in COVID-19 as previously estimated: The overall prevalence was 7.7% (95% CI 7.4 to 8.6%) for diarrhoea, 7.8% (95% CI: 7.1 to 8.5%) for nausea/vomiting, and 3.6% (95% CI 3.0 to 4.3%) for abdominal pain. Notably, in outpatients, the pooled prevalence of diarrhoea is lower (4.0%).
- However, COVID-19 can present atypically, with GI symptoms: COVID-19 can present with diarrhoea as an initial symptom, with a pooled prevalence of 7.9% across 35 studies, encompassing 9717 patients. Most often, diarrhoea is accompanied by other upper respiratory infection symptoms. However, in some cases, diarrhoea can precede other symptoms by a few days, and COVID-19 may present as isolated GI symptoms prior to the development of upper respiratory infection symptoms.
- Monitor patients with new diarrhoea, nausea or vomiting for other COVID-19 symptoms: Patients should inform gastroenterologists if they begin to experience new fever, cough, shortness of breath or other upper respiratory infection symptoms after the onset of GI symptoms. If this occurs, testing for COVID-19 should be considered.
- Abnormalities in liver function tests should prompt thorough evaluation: Liver test abnormalities can be seen in COVID-19 (in approximately 15% of patients); however, available data support that these abnormalities are more commonly attributable to secondary effects from severe disease, rather than primary virus-mediated liver injury. Therefore, it is important to consider alternative aetiologies, such as viral hepatitis, when new elevations in aminotransferases are observed.
